Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine.
CCL21
PD-1
T cells
dendritic cells (DC)
lung cancer
tumor microenvironment (TME)
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
05 Nov 2020
05 Nov 2020
Historique:
received:
31
08
2020
revised:
02
10
2020
accepted:
03
10
2020
entrez:
10
11
2020
pubmed:
11
11
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Immune checkpoint blockade that downregulates T cell evasion for effective immunity has provided a renewed interest in therapeutic cancer vaccines. Utilizing murine lung cancer models, we determined: tumor burden, TIL cytolysis, immunohistochemistry, flow cytometry, RNA Sequencing, CD4 T cells, CD8 T cells, CXCL9 chemokine, and CXCL10 chemokine neutralization to evaluate the efficacy of Programmed cell death protein 1 (PD-1) blockade combined with chemokine (C-C motif) ligand 21-dendritic cell tumor antigen (CCL21-DC tumor Ag) vaccine. Anti-PD1 combined with CCL21-DC tumor Ag vaccine eradicated 75% of 12-day established tumors (150 mm PD-1 blockade therapy plus CCL21-DC tumor Ag vaccine could be beneficial to lung cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint blockade that downregulates T cell evasion for effective immunity has provided a renewed interest in therapeutic cancer vaccines.
METHODS
METHODS
Utilizing murine lung cancer models, we determined: tumor burden, TIL cytolysis, immunohistochemistry, flow cytometry, RNA Sequencing, CD4 T cells, CD8 T cells, CXCL9 chemokine, and CXCL10 chemokine neutralization to evaluate the efficacy of Programmed cell death protein 1 (PD-1) blockade combined with chemokine (C-C motif) ligand 21-dendritic cell tumor antigen (CCL21-DC tumor Ag) vaccine.
RESULTS
RESULTS
Anti-PD1 combined with CCL21-DC tumor Ag vaccine eradicated 75% of 12-day established tumors (150 mm
CONCLUSION
CONCLUSIONS
PD-1 blockade therapy plus CCL21-DC tumor Ag vaccine could be beneficial to lung cancer patients.
Identifiants
pubmed: 33167311
pii: vaccines8040655
doi: 10.3390/vaccines8040655
pmc: PMC7712481
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Oncoimmunology. 2013 May 1;2(5):e24036
pubmed: 23762792
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Cell Mol Immunol. 2013 May;10(3):222-9
pubmed: 23524654
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
J Immunol. 2006 Feb 1;176(3):1582-7
pubmed: 16424187
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Genome Med. 2018 Nov 29;10(1):93
pubmed: 30497521
Oncoimmunology. 2015 Apr 27;4(4):e992237
pubmed: 26137407
Biotechniques. 2007 Nov;43(5):575, 577-8, 581-2 passim
pubmed: 18072586
Cell. 2000 May 26;101(5):455-8
pubmed: 10850488
Cancer Cell. 2018 Oct 8;34(4):690
pubmed: 30300584
PLoS One. 2012;7(7):e40677
pubmed: 22815789
J Clin Immunol. 2007 May;27(3):317-26
pubmed: 17468835
Vaccines (Basel). 2020 Jun 18;8(2):
pubmed: 32570793